Michael Rytting

Medicine · Health Sciences

36h-index6.3kcitations145works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(83), Acute Myeloid Leukemia Research(36), Chronic Lymphocytic Leukemia Research(35), Childhood Cancer Survivors' Quality of Life(31), Glioma Diagnosis and Treatment(16)

Publications144 total

Data from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary material and methods, Tables 1-3 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 1 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary material and methods, Tables 1-3 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 2 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 2 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Data from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 1 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2023Open Access
Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives
Pediatric Drugs·2021· 18 cited
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Leukemia·2021· 167 citedOpen Access
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma
Journal of Pediatric Hematology/Oncology·2021· 14 cited
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia
Pediatric Blood & Cancer·2020· 13 citedOpen Access
Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents
Hematologic malignancies·2020
Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review
Journal of Pediatric Hematology/Oncology·2020· 8 cited
Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma
Neuro-Oncology·2020· 83 citedOpen Access
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib
Blood·2019· 3 cited
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Blood·2019· 7 cited
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
Blood·2019· 13 cited
Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms
Blood·2019· 3 cited
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Blood·2019· 21 cited
page 1 of 8Next →

Frequent Co-authors

Hagop M. Kantarjian(25), Jörge E. Cortes(17), Farhad Ravandi(17), Elias Jabbour(17), Guillermo Garcia‐Manero(15), Susan O’Brien(14), Deborah A. Thomas(12), Marina Konopleva(10), Tapan M. Kadia(10), Gautam Borthakur(9), Sima Jeha(9), Sherry Pierce(7), Rebecca Garris(7), Naval Daver(7), Jeffrey L. Jorgensen(6), Partow Kebriaei(6), Nitin Jain(6), Nicholas J. Short(5), William G. Wierda(5), Stefan Faderl(5)